

Figure S1 The Markov model simulated with three health states: progression-free survival, progressed disease and death.

Figure S2 Estimated best-fitting survival curves for overall survival (A, B) and progression-free survival (C, D) derived from the NAPOLI 3 trial.

Figure S3 The cost-effectiveness acceptability curves for probabilistic sensitivity analyses in metastatic pancreatic ductal adenocarcinoma.

Figure S4 The cost-effectiveness acceptability curves for probabilistic sensitivity analyses in mPDAC. WTP thresholds of \$50,000/QALY, \$100,000/QALY and \$150,000/QALY are depicted. The price of liposomal irinotecan/mg is reduced by 50%, 75%, 78%, 89%, 98% respectively.




Figure S1 The Markov model simulated with three health states: progression-free survival, progressed disease and death.







Figure S2 Estimated best-fitting survival curves for overall survival (A, B) and progression-free survival (C, D) derived from the NAPOLI 3 trial.




Figure S3 The cost-effectiveness acceptability curves for probabilistic sensitivity analyses in mPDAC. WTP thresholds of \$100,000/QALY and \$150,000/QALY are depicted.

Figure S4 The cost-effectiveness acceptability curves for probabilistic sensitivity analyses in mPDAC. WTP thresholds of \$50,000/QALY, \$100,000/QALY and \$150,000/QALY are depicted. The price of liposomal irinotecan/mg is reduced by 50%, 75%, 78%, 89%, 98% respectively.

